Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip van den Bosch

Showing results (21-30 of 192) with videos related to

Pageof 20
Sort By:
Rheumatic Diseases Clinics of North America|October 23, 2012
Pathophysiology and role of the gastrointestinal system in spondyloarthritidesPeggy Jacques, Liesbet Van Praet, Philippe Carron, et al.
The Journal of Rheumatology|April 3, 2015
Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestationsFilip Van den Bosch, Arthur Kavanaugh, Martina Kron, et al.
Rheumatic Diseases Clinics of North America|October 23, 2012
Therapy for spondyloarthritis: the role of extra-articular manifestations (eye, skin)Philippe Carron, Liesbet Van Praet, Peggy Jacques, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 29, 2018
High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral SpondyloarthritisPhilippe Carron, Gaëlle Varkas, Thomas Renson, et al.
Seminars in Arthritis and Rheumatism|July 1, 2021
Axial involvement in psoriatic arthritis: An update for rheumatologistsDenis Poddubnyy, Deepak R Jadon, Filip Van den Bosch, et al.
International Journal of Rheumatic Diseases|April 17, 2019
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohortPascal Claudepierre, Filip Van den Bosch, Piercarlo Sarzi-Puttini, et al.
Annals of the Rheumatic Diseases|February 19, 2017
Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA studyPhilippe Carron, Gaëlle Varkas, Heleen Cypers, et al.
Arthritis Care & Research|June 26, 2024
When Usual Care Is Not So Usual: Protocol Violations and Generalizability in a Treat-to-Target Strategy Trial in Patients With Axial SpondyloarthritisClementina López-Medina, Filip van den Bosch, Désirée van der Heijde, et al.
Clinical and Experimental Rheumatology|August 28, 2018
Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS studyFilip Van den Bosch, Rene-Marc Flipo, Jürgen Braun, et al.
Rheumatology (Oxford, England)|October 6, 2022
Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trialSimon Krabbe, Thomas Renson, Lennart Jans, et al.
Pageof 20

Showing results (21-30 of 192) with videos related to

Sort By:
Pageof 20
Rheumatic Diseases Clinics of North America|October 23, 2012
Pathophysiology and role of the gastrointestinal system in spondyloarthritidesPeggy Jacques, Liesbet Van Praet, Philippe Carron, et al.
The Journal of Rheumatology|April 3, 2015
Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestationsFilip Van den Bosch, Arthur Kavanaugh, Martina Kron, et al.
Rheumatic Diseases Clinics of North America|October 23, 2012
Therapy for spondyloarthritis: the role of extra-articular manifestations (eye, skin)Philippe Carron, Liesbet Van Praet, Peggy Jacques, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 29, 2018
High Rate of Drug-Free Remission After Induction Therapy With Golimumab in Early Peripheral SpondyloarthritisPhilippe Carron, Gaëlle Varkas, Thomas Renson, et al.
Seminars in Arthritis and Rheumatism|July 1, 2021
Axial involvement in psoriatic arthritis: An update for rheumatologistsDenis Poddubnyy, Deepak R Jadon, Filip Van den Bosch, et al.
International Journal of Rheumatic Diseases|April 17, 2019
Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohortPascal Claudepierre, Filip Van den Bosch, Piercarlo Sarzi-Puttini, et al.
Annals of the Rheumatic Diseases|February 19, 2017
Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA studyPhilippe Carron, Gaëlle Varkas, Heleen Cypers, et al.
Arthritis Care & Research|June 26, 2024
When Usual Care Is Not So Usual: Protocol Violations and Generalizability in a Treat-to-Target Strategy Trial in Patients With Axial SpondyloarthritisClementina López-Medina, Filip van den Bosch, Désirée van der Heijde, et al.
Clinical and Experimental Rheumatology|August 28, 2018
Clinical and quality of life improvements with golimumab or infliximab in a real-life ankylosing spondylitis population: the QUO-VADIS studyFilip Van den Bosch, Rene-Marc Flipo, Jürgen Braun, et al.
Rheumatology (Oxford, England)|October 6, 2022
Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trialSimon Krabbe, Thomas Renson, Lennart Jans, et al.
Pageof 20